Mostrar el registro sencillo del ítem

Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study

dc.creatorApiquián, Rogelio
dc.creatorUlloa, Elena
dc.creatorFresán, Ana
dc.creatorLoyzaga, Cristina
dc.creatorNicolini, Humberto
dc.creatorKapur, Shitij
dc.date.accessioned2017-06-30T03:42:25Z
dc.date.available2017-06-30T03:42:25Z
dc.date.issued2002es_ES
dc.identifier2141es_ES
dc.identifier.issn0920-9964es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/6796
dc.identifier.urihttps://doi.org/10.1016/S0920-9964(01)00342-5es_ES
dc.language.isoenges_ES
dc.publisherELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSes_ES
dc.relation59 (1) 35-39 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.titleAmoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label studyes_ES
dc.typearticlees_ES
dc.contributor.affiliationCarracci Medical Group, Mexico City, Mexicoes_ES
dc.contributor.emailskapur@camhpet.on.caes_ES
dc.relation.jnabreviadoSCHIZOPHR RESes_ES
dc.relation.journalSchizophrenia Researches_ES
dc.identifier.placeAmsterdames_ES
dc.date.published2002es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.eissn1573-2509es_ES
dc.description.abstractotrodiomaObjective: Amoxapine is marketed as an antidepressant. However, its receptor occupancy, in vitro and in vivo, and its effects in pre-clinical models are very similar to atypical antipsychotics. To examine if this leads to an atypical antipsychotic effect in the clinical context, the authors examined the antipsychotic and side-effect profile of amoxapine in acutely psychotic patients with schizophrenia. Methods: Seventeen patients were enrolled and 15 completed a prospective open-label 6-week study of amoxapine starting with a fixed-starting dose (150 mg/h) with standardized titration up to 250 mg/h, if required. Positive, negative, affective symptoms and side-effects were monitored using standardized weekly assessments. Results: Amoxapine (median final dose 210 mg/h) was well-tolerated and showed significant improvement in positive and negative symptoms (both p<0.001), with a trend towards improvement in mood symptoms and no treatment-emergent extrapyramidal side-effects, akathisia or weight gain. Prolactin elevation was observed. Conclusion: These clinical data lend support to the pre-clinical suggestions that amoxapine may be an atypical antipsychotic. Given its lack of weight gain and that it is considerably less expensive than current options, amoxapine could be a valuable alternative for some patients. These considerations strongly call for more systematic, double-blind studies of amoxapine as an atypical antipsychotic.es_ES
dc.subject.koAntipsychotices_ES
dc.subject.koAtypicales_ES
dc.subject.koSchizophreniaes_ES
dc.subject.koAntidepressantes_ES
dc.subject.koSerotonines_ES
dc.subject.koDopaminees_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem